Laurence Bresson-bepoldin

Dr. Laurence Bresson-bepoldin


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NKNadine Khadra
Nadine Khadra
LBLaurence Bresson-bepoldin
Laurence Bresson-bepoldin
APAubin Penna
Aubin Penna
BCBenjamin Chaigne-Delalande
Benjamin Chaigne-Delalande
BSBruno Ségui
Bruno Ségui
Patrick LegembrePatrick Legembre
Patrick Legembre
The death receptor CD95 plays a pivotal role in immune surveillance and immune tolerance. Binding of CD95L to CD95 leads to recruitment of the adaptor protein Fas-associated death domain protein (FADD), which in turn aggregates caspase-8 and caspase-10. Efficient formation of the CD95/FADD/caspase complex, known as the death-inducing signaling complex (DISC), culminates in the induction of apoptosis. We show that cells exposed to CD95L undergo a reorganization of the plasma membrane in which the Ca2+release-activated Ca2+channel Orai1 and the endoplasmic reticulum-resident activator stromal interaction molecule 1 colocalize with CD95 into a micrometer-sized cluster in which the channel elicits a polarized entry of calcium. Orai1 knockdown and expression of a dominant negative construct (Orai1E106A) reveal that on CD95 engagement, the Orai1-driven localized Ca2+influx is fundamental to recruiting the Ca2+-dependent protein kinase C (PKC) β2 to the DISC. PKCβ2 in turn transiently holds the complex in an inactive status, preventing caspase activation and transmission of the apoptotic signal. This study identifies a biological role of Ca2+and the Orai1 channel that drives a transient negative feedback loop, introducing a lag phase in the early steps of the CD95 signal. We suggest that these localized events provide a time of decision to prevent accidental cell death.

14 May 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
AGAnne-Sophie Gallouet
Anne-Sophie Gallouet
MTMarion Travert
Marion Travert
LBLaurence Bresson-bepoldin
Laurence Bresson-bepoldin
FGFabien Guilloton
Fabien Guilloton
CPCeline PANGAULT
Celine PANGAULT
TGThierry Guillaudeux
Thierry Guillaudeux
Purpose: Despite therapeutic advances, non–Hodgkin lymphomas (NHL) remain incurable. They form a group of neoplasms strongly dependent on their inflammatory microenvironment, which plays an important supportive role in tumor B-cell survival and in the resistance to antitumor immune response. New therapies must consider both tumor cells and their surrounding microenvironmentExperimental Design: Stromal cells, derived from bone marrow or lymph nodes, and B cells from follicular lymphoma patients were cocultured or cultured alone with celecoxib treatment, a nonsteroidal anti-inflammatory drug, and/or TRAIL, a promising cytotoxic molecule for cancer therapy.Results: In this study, we show that follicular lymphoma stromal cells produce large amounts of PGE2. This production is abrogated after celecoxib treatment, targeting the COX-2 isoenzyme involved in PGE2 synthesis. Furthermore, we demonstrate that celecoxib increases apoptosis in NHL B-cell lines and in primary follicular lymphoma B cells cocultured with stromal cells, but independently of the PGE2/COX-2 axis. Finally, celecoxib increases the apoptotic activity of TRAIL. We provide evidence that celecoxib affects proliferation and sensitizes NHL B-cell lines to apoptosis through COX-2–independent effects by slowing down the cell cycle and decreasing the expression of survival proteins, such as Mcl-1.Conclusions: These data suggest new potent strategies for NHL therapy combining drugs targeting both tumor B cells and survival signals provided by the tumor microenvironment. Clin Cancer Res; 20(10); 2663–73. ©2014 AACR.

9 December 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
CLClaire Lamaison
Claire Lamaison
SLSimon Latour
Simon Latour
NHNelson Hélaine
Nelson Hélaine
VMValérie Le Morvan
Valérie Le Morvan
JSJulien Saint-Vanne
Julien Saint-Vanne
LBLaurence Bresson-bepoldin
Laurence Bresson-bepoldin
Non-Hodgkin B-cell lymphomas (B-NHL) mainly develop within lymph nodes as aggregates of tumor cells densely packed with their surrounding microenvironment, creating a tumor niche specific to each lymphoma subtypes. In vitro preclinical models mimicking biomechanical forces, cellular microenvironment, and 3D organization of B-cell lymphomas remain scarce, while all these parameters are key determinants of lymphomagenesis and drug resistance. Using a microfluidic method based on cell encapsulation inside permeable, elastic, and hollow alginate microspheres, we developed a new tunable 3D model incorporating lymphoma B cells, extracellular matrix (ECM), and/or tonsil stromal cells (TSC). Under 3D confinement, lymphoma B cells were able to form cohesive spheroids resulting from overexpression of ECM components. Moreover, lymphoma B cells and TSC dynamically formed self-organized 3D spheroids favoring tumor cell growth. 3D culture induced resistance to the classical chemotherapeutic agent doxorubicin, but not to the BCL2 inhibitor ABT-199, identifying this approach as a relevant in vitro model to assess the activity of therapeutic agents in B-NHL. RNA-sequence analysis highlighted the synergy of 3D, ECM, and TSC in upregulating similar pathways in malignant B cells in vitro than those overexpressed in primary lymphoma B cells in situ. Finally, our 3D model including ECM and TSC allowed long-term in vitro survival of primary follicular lymphoma B cells. In conclusion, we propose a new high-throughput 3D model mimicking lymphoma tumor niche and making it possible to study the dynamic relationship between lymphoma B cells and their microenvironment and to screen new anti-cancer drugs.

1 September 2015 in The Journal of Immunology
Verified
Journal Article
Closed access
VVVACHER Vacher
VACHER Vacher
AVAnne-Marie Vacher
Anne-Marie Vacher
RPRaphael Pineau
Raphael Pineau
SLSimon Latour
Simon Latour
ISIsabelle Soubeyran
Isabelle Soubeyran
LBLaurence Bresson-bepoldin
Laurence Bresson-bepoldin
The anti-CD20 mAb, rituximab, is routinely used to treat B cell malignancies. However, a majority of patients relapse. An improvement in the complete response was obtained by combining rituximab with chemotherapy, at the cost of increased toxicity. We reported that rituximab induced the colocalization of both the Orai1 Ca2+ release-activated Ca2+ channel (CRAC) and the endoplasmic reticulum Ca2+ sensor stromal interaction molecule 1 with CD20 and CD95 into a cluster, eliciting a polarized store-operated Ca2+ entry (SOCE). We observed that blocking this Ca2+ entry with downregulation of Orai1, pharmacological inhibitors, or reducing calcemia with hypocalcemic drugs sensitized human B lymphoma cell lines and primary human lymphoma cells to rituximab-induced apoptosis in vitro, and improved the antitumoral effect of rituximab in xenografted mice. This revealed that Ca2+ entry exerted a negative feedback loop on rituximab-induced apoptosis, suggesting that associating CRAC channel inhibitors or hypocalcemic agents with rituximab may improve the treatment of patients with B cell malignancies. The calcium-dependent proteins involved in this process appear to vary according to the B lymphoma cell type, suggesting that CRAC-channel targeting is likely to be more efficient than calcium-dependent protein targeting.

20 March 2002 in Glia
Verified
Journal Article
Closed access
PDF file
TDThomas Ducret
Thomas Ducret
SBSihem Boudina
Sihem Boudina
BSBruno Sorin
Bruno Sorin
AVAnne Marie Vacher
Anne Marie Vacher
IGIsabelle Gourdou
Isabelle Gourdou
VVVACHER Vacher
VACHER Vacher

1 March 1994 in Cell Calcium
Verified
Journal Article
Closed access
LBLaurence Bresson-bepoldin
Laurence Bresson-bepoldin
LDL. Dufy-Barbe
L. Dufy-Barbe